Literature DB >> 1721890

Phenotyping of T-cell lymphomas in paraffin sections--which antibodies?

J M Cabeçadas1, P G Isaacson.   

Abstract

Five antibodies, MT1 (CD43), UCHL1 (CD45RO), OPD4, poly-CD3 and beta F1, were assessed for their reactivity with 50 archival cases of T-cell lymphoma in formalin-fixed paraffin-embedded tissue. All cases had been previously characterized as T-cell lymphomas, and the histological types included 14 cases of small cerebriform lymphoma, six cases of angioimmunoblastic lymphadenopathy-like T-cell lymphoma, four cases of T-zone lymphoma, five cases of pleomorphic small cell lymphoma, 12 cases of pleomorphic medium and large cell lymphoma, four cases of anaplastic large cell lymphoma, two cases of T-lymphoblastic lymphoma and three cases of enteropathy-associated T-cell lymphoma. UCHL1 and MT1 showed reactivity with the highest percentage of cases (94 and 86% respectively) but lack absolute specificity for T-cells, especially in high-grade lymphomas. Poly-CD3 is highly specific for T-cells, and stained neoplastic cells in almost 80% of the cases. beta F1 stained the lowest percentage of cases (40%). UCHL1 and poly-CD3 together identified 98% of cases, and this combination is recommended for the diagnosis of T-cell lymphomas in paraffin sections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721890     DOI: 10.1111/j.1365-2559.1991.tb00231.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  2 in total

1.  Diagnosis and treatment of lymphomatoid granulomatosis.

Authors:  S Senan
Journal:  Postgrad Med J       Date:  1992-10       Impact factor: 2.401

2.  Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathological conditions.

Authors:  F Facchetti; J K Chan; W Zhang; A Tironi; M Chilosi; S Parolini; L D Notarangelo; L E Samelson
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.